Ensysce Biosciences, Inc. (ENSC): history, ownership, mission, how it works & makes money

A Brief History of Ensysce Biosciences, Inc. (ENSC)

Company Formation and Initial Developments

Ensysce Biosciences, Inc. (formerly known as Ensysce Pharmaceuticals) was founded in 2016 with a focus on developing solutions for pain management and abuse deterrence in opioid medications. The company's headquarters is located in San Diego, California.

Public Offering and Stock Performance

Ensysce went public on the NASDAQ under the ticker symbol ENSC in 2021. As of October 2023, the company’s stock price fluctuates around $0.50, reflecting its ongoing development phase and the challenges within the biotech sector.

Key Products and Innovations

The company is known for its innovative technology platforms, including:

• TPP (Targeted Pain Prevention) - Aimed at reducing opioid dependency and abuse.
• PTI (Pain Treatment Initiator) - Focused on treating pain while minimizing the risks associated with traditional opioid therapies.

In 2022, Ensysce announced the successful results of its Phase 1 clinical trials for TPP, showing a promising efficacy profile.

Financial Overview

As of Q2 2023, Ensysce Biosciences reported a cash position of approximately $3 million, which is allocated for ongoing clinical trials and operational costs. The company recorded a net loss of $2.5 million for the quarter, reflecting the high costs typically associated with biotech development.

Partnerships and Collaborations

Ensysce has formed strategic partnerships with several organizations to further its research:

• Collaboration with the University of California, San Diego - Focused on advancing pain management therapies.
• Alliance with other biotech firms to enhance drug development pipelines.

Future Directions

The strategic plan for Ensysce includes advancing its clinical trials for TPP and PTI, seeking additional funding, and partnerships to enhance its research capabilities. The company aims to establish a robust presence in the pain management market by addressing the opioid crisis.

Regulatory Milestones

Ensysce has been actively engaged in seeking regulatory approvals from the FDA, with the hope of filing Investigational New Drug (IND) applications in the near future for its key product candidates.

Market Outlook

The global pain management market is projected to reach approximately $80 billion by 2027, which underscores the significant opportunity for Ensysce's innovative solutions in this space.

A Who Owns Ensysce Biosciences, Inc. (ENSC)

Company Overview

Ensysce Biosciences, Inc. (ENSC) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutic solutions aimed at pain management and drug delivery. The company is publicly traded on NASDAQ under the ticker symbol ENSC.

Shareholder Structure

The ownership of Ensysce Biosciences can be broken down into various categories of investors. The following table illustrates the ownership distribution as of the most recent filings:

Major Institutional Investors

The following table lists some of the major institutional investors in Ensysce Biosciences, along with their respective ownership stakes:

Insider Ownership and Key Executives

Insider ownership plays a critical role in the governance of Ensysce Biosciences. The following table highlights the key executives and their ownership stakes:

Recent Stock Performance

As of the latest trading session, Ensysce Biosciences (ENSC) stock is priced at $4.85. The market capitalization is approximately $65 million, with trading volume averaging around 250,000 shares per day.

Future Projections

Analysts project a potential upside for Ensysce Biosciences based on its clinical developments, with estimates suggesting a target price of $8.00 per share over the next 12 months, reflecting a potential growth of approximately 65% from the current price.

Ensysce Biosciences, Inc. (ENSC) Mission Statement

Core Mission

Ensysce Biosciences, Inc. is dedicated to advancing the field of biotechnology by innovating safer and more effective pain management therapies. The company focuses on developing its proprietary technologies, specifically its ProTect™ and Rescue™ platforms.

Business Objectives

• To enhance patient outcomes through non-opioid therapeutic solutions.
• To utilize advanced drug delivery systems to reduce the abuse potential of medications.
• To achieve commercial success through strategic partnerships and collaborations.
• To maintain a strong pipeline of clinical candidates targeting significant unmet medical needs.

Financial Overview

As of the latest financial report, Ensysce Biosciences has demonstrated a commitment to growth and innovation:

Strategic Partnerships

The company has formed several strategic partnerships to enhance its research and development capabilities:

• University Collaborations: Partnership with institutions for clinical research.
• Pharmaceutical Collaborations: Agreements with major pharmaceutical companies for drug development.
• Investment Partnerships: Engaging with investors to support funding for ongoing projects.

Technological Innovations

Ensysce's innovative technologies focus on:

• ProTect™: A platform designed to mitigate the potential for drug misuse.
• Rescue™: Designed to reverse opioid overdoses effectively.

Clinical Development Pipeline

The clinical pipeline consists of various stages of development:

Commitment to Safety

Ensysce prioritizes patient safety and the reduction of opioid-related harm through:

• Development of formulations with reduced abuse potential.
• Conducting rigorous clinical trials to ensure efficacy and safety.
• Adopting regulatory compliance measures strictly to guarantee product safety.

Future Vision

The vision of Ensysce Biosciences is to be a leader in innovative therapies that redefine pain management, ultimately aiming to:

• Improve the quality of life for patients.
• Address the public health crisis of opioid dependence.
• Expand into global markets with its therapeutic solutions.

How Ensysce Biosciences, Inc. (ENSC) Works

Company Overview

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company focusing on developing innovative pain management therapies. The company utilizes its proprietary technology to enhance the safety and efficacy of opioid medications.

Business Model

• Focus on developing safe pain management solutions.
• Utilization of the ProTect technology to mitigate opioid abuse potential.
• Collaboration with pharmaceutical partners for drug development and commercialization.
• Investment in clinical trials to validate drug efficacy and safety.

Key Technologies

Ensysce's primary technologies include:

• ProTect Technology: A proprietary approach aimed at reducing the potential for opioid misuse.
• Ensysce’s CNS-7056: A novel formulation designed for pain relief with lower abuse potential.

Financial Overview

The following table summarizes the key financial metrics for Ensysce Biosciences, Inc. as of the latest available data:

Research and Development

Ensysce invests significantly in research and development (R&D) to advance its pipeline. As per the 2022 report, R&D expenses were approximately $6.5 million.

Clinical Trials

The company is engaged in several clinical trials for its lead product candidates:

• Clinical Stage: Phase 2/3 trials for CNS-7056.
• Trial Locations: Multiple sites across the United States.
• Participants: Targeting enrollment of 300 patients.

Regulatory Approvals

Ensysce is working towards gaining regulatory approval for its drug candidates:

• FDA meetings held to discuss the development plan.
• Potential submission for New Drug Application (NDA) projected for late 2024.

Market Position

Ensysce operates in the pain management market, projected to reach approximately $110 billion by 2025. The opioid crisis drives the demand for safer alternatives, which positions Ensysce favorably.

Collaboration and Partnerships

Ensysce has established partnerships to enhance its research capabilities:

• Collaboration with academic institutions for drug development.
• Potential licensing agreements with larger pharmaceutical companies.

Stock Performance

As of October 2023, Ensysce's stock (ENSC) has the following performance metrics:

Future Outlook

Ensysce aims to expand its product pipeline and seeks to secure additional funding to support ongoing clinical trials and operational costs.

How Ensysce Biosciences, Inc. (ENSC) Makes Money

Business Model Overview

Ensysce Biosciences, Inc. generates revenue primarily through the development and commercialization of innovative drug delivery systems, particularly in the areas of pain management and addiction treatment. The company's unique technologies focus on improving the safety and efficacy of opioid medications.

Revenue Streams

• Product Sales
• Partnerships and Collaborations
• Grants and Funding
• Intellectual Property Licensing

Product Sales

Ensysce is actively developing products such as:

• PF614 (a tamper-resistant formulation of hydromorphone)
• PF614-MPAR (multi-particulate abuse-resistant technology)

As of Q3 2023, the company's projected revenue from product sales for PF614 is estimated at $10 million in the first year following market approval.

Partnerships and Collaborations

Ensysce has secured various partnerships to enhance its development capabilities:

• Collaboration with a major pharmaceutical company for PF614 development
• Partnership with academic institutions for research initiatives

The financial details of these partnerships often include milestone payments. For instance, Ensysce could receive up to $25 million in milestone payments from partners depending on the achievement of certain clinical and regulatory targets.

Grants and Funding

The company has been awarded several grants, particularly to support its research activities:

• NIDA grant to support opioid-related research: $2 million
• NIH grant for pain management research: $1.5 million

In 2023, the total amount of grants received was approximately $3.5 million.

Intellectual Property Licensing

Ensysce's intellectual property portfolio allows it to monetize its innovations through licensing:

• Licenses granted for its proprietary abuse-deterrent technologies
• Revenue from licensing agreements is estimated at $1 million annually

As of 2023, the total revenue from licensing deals accounted for approximately 10% of total revenue.

Financial Performance Summary

The company's financial performance can be summarized as follows:

Market Potential and Future Growth

Ensysce is positioned to tap into the growing market for pain management solutions. The global opioid market was valued at approximately $24 billion in 2023 and is projected to reach $37 billion by 2030. Ensysce aims to capture a significant share of this market through its innovative product offerings.

Regulatory Approvals and Market Entry

Achieving regulatory approval is crucial for revenue generation:

• Anticipated FDA submission for PF614 in Q4 2023
• Expected market entry in late 2024

Conclusion on Growth Potential

With various revenue-generating avenues and a favorable market landscape, Ensysce Biosciences, Inc. is poised for potential financial growth. The successful commercialization of its products will significantly enhance its revenue streams.